© 2026 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 161 Farringdon Rd, London EC1R 3AL. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions | Cookies

Health and Biotech

Top Section/Ad

Top Section/Ad

Most recent


Offer came as markets recovered and volatility fell
Latest block this week in volatile conditions
Abbott Laboratories plundered $20bn as it led a trio of drug companies which printed jumbo bonds as a deluge of supply in the dollar market ensured a red-hot end to the month.
More articles/Ad

More articles/Ad

More articles

  • Indonesian quasi-sovereign construction firm Hutama Karya launched its first dollar bond on Monday, raising $600m from a 10 year deal despite the Covid-19 pandemic challenging the market.
  • Argentine government bonds have sold off yet again as neither creditors nor the government appear willing to blink in a stalemate that is likely to lead the sovereign to default on May 22, when the grace period expires on $500m of bond payments.
  • United Overseas Bank has approved S$4bn ($2.8bn) in loans to mid-sized enterprises in Singapore, taking advantage of a temporary bridging loan programme launched by the country’s government to cushion the impact of the Covid-19 pandemic on companies.
  • Telecoms giant América Móvil on Monday became the first private sector non-financial company from Latin America to issue a bond since the coronavirus pandemic battered emerging market bond markets in March. But the company’s unique appeal to non-EM buyers means few conclusions can be drawn about appetite for genuine Lat Am companies.
  • The operator of Santiago de Chile’s metro system, Metro, found ample demand for a new dual tranche issue on Monday as investors continue to show appetite for highly rated government-related issuers even at tight new issue concessions. The borrower's state support means it is a in a strong position to do Latin America's first buy-back of the pandemic.
  • Mainland-based Peijia Medical is set to be the third healthcare company to list in Hong Kong since the coronavirus outbreak in late January, opening books on Tuesday for a HK$2.34bn ($302m) IPO.